Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT06323785

Whole-body Hyperthermia for Depression

Led by University of Zurich · Updated on 2024-06-11

30

Participants Needed

1

Research Sites

89 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to test the efficacy of whole-body hyperthermia in major depression. The main question it aims to answer is: • Does whole-body hyperthermia alleviate symptoms of depression? Participants will be randomised to sham or active whole-body hyperthermia. The study will last 6 weeks during which five visits will take place. Depression will be measured repeatedly and biological mechanisms will be investigated.

CONDITIONS

Official Title

Whole-body Hyperthermia for Depression

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Mental capacity to make decisions
  • Signed informed consent
  • Fluent in the German language
  • Age between 18 and 65 years
  • Pre-menopausal women willing to use birth control or refrain from sexual intercourse during the study if this matches their usual lifestyle
  • Meet DSM-5 criteria for a major depressive episode
  • Score of 14 or higher on the Hamilton Rating Scale for Depression (HAMD-17)
  • Major depression is the primary mental disorder
Not Eligible

You will not qualify if you...

  • Vulnerable subjects
  • Known or suspected non-compliance, drug or alcohol abuse within the past 2 years
  • Inability to follow study procedures due to language problems, psychological disorders, dementia, or similar
  • Participation in another investigational drug or medical device study within 30 days prior or during this study
  • Previous enrollment in this study
  • Enrollment of Sponsor-Investigator, family, employees, or dependents
  • Contraindications or limitations of the medical device per instructions for use
  • Body Mass Index (BMI) over 30
  • Lifetime diagnosis of schizophrenia or bipolar disorder
  • Current catatonic or psychotic symptoms
  • Current suicidal thoughts
  • Severe claustrophobia
  • Anorexia or bulimia nervosa within the past 5 years
  • Presence of metallic, silicone, or saline implants
  • Cardiovascular problems including uncontrolled hypertension, congestive heart failure, or coronary artery disease
  • Chronic diseases affecting thermoregulation such as Parkinson's, multiple sclerosis, CNS tumors, or diabetic neuropathy
  • History of peripheral circulatory disease, deep vein thrombosis, cerebral vascular accident, epilepsy, or cerebral aneurysms
  • Cancer diagnosis within the last 5 years except for removed non-melanoma skin cancer
  • Clinically significant autoimmune diseases
  • Hemophilia or bleeding tendency
  • Fever on the day of study intervention
  • Sensitivity to heat
  • Recent acute joint injury
  • Active infections including dental or joint infections
  • Any unstable or clinically significant medical condition that could affect safety or study assessments
  • Use of medications that interfere with thermoregulation such as barbiturates, diuretics, beta-blockers, or antihistamines
  • Use of psychotropic medication within 2 weeks (8 weeks for fluoxetine)
  • Need for psychotropic medication during the study
  • Current psychotherapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Zurich, Institute of Psychology

Zurich, Switzerland, 8050

Actively Recruiting

Loading map...

Research Team

S

Susanne Fischer, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here